Antibiotic therapy against Pseudomonas aeruginosa in cystic fibrosis: a European consensus

Cystic fibrosis (CF) is the most common lethal hereditary disorder with autosomal recessive heredity in caucasians. The majority of CF patients suffer from chronic respiratory infection with the opportunistic bacterial pathogen Pseudomonas aeruginosa. No consensus among clinicians has been reached so far concerning antibiotic treatment against P. aeruginosa in CF patients. Consensus answers to 24 important questions in this context, based on current evidence, are presented, given by a panel of 34 European experts. Questions addressed and answered are: The diagnosis of P. aeruginosa lung colonization in CF; The impact of P. aeruginosa on the clinical state of CF patients; The assessment of P. aeruginosa susceptibility against antibiotics and the importance of these results for the clinician; The use of monotherapy versus combination therapy; The development of microbial resistance; The achievement of optimal airway concentrations; The effects of subinhibitory concentrations of antibiotics on P. aeruginosa; Statements on the pharmacokinetics of antibiotics in CF patients; Recommendations for doses and dosing intervals and length of treatment regimens; and Toxic side effects due to repeated antibiotic therapy was addressed. The expert panel answered further questions on the use of fluoroquinolones in children with CF, on the administration of nebulized antibiotics and whether prevention of P. aeruginosa lung colonization is possible in CF using antibiotic therapy. Problems of antibiotic therapy at home and in the hospital were addressed, a consensus statement on regular maintenance treatment, or treatment on demand, was given and different routes of administration of antibiotics were recommended for different clinical situations. Finally, the factors which determine the choice of the antibiotic, the dosage, and the duration of the treatment in cystic fibrosis patients were addressed and the design of future antibiotic studies in the context of Pseudomonas aeruginosa lung infection in cystic fibrosis patients were recommended.

This article has been cited by other articles:

				K. Sanderson, L. Wescombe, S. M. Kirov, A. Champion, and D. W. Reid Bacterial cyanogenesis occurs in the cystic fibrosis lung Eur. Respir. J., August 1, 2008; 32(2): 329 - 333. [Abstract] [Full Text] [PDF]

				W. J. Kozlowska, A. Bush, A. Wade, P. Aurora, S. B. Carr, R. A. Castle, A.-F. Hoo, S. Lum, J. Price, S. Ranganathan, et al. Lung Function from Infancy to the Preschool Years after Clinical Diagnosis of Cystic Fibrosis Am. J. Respir. Crit. Care Med., July 1, 2008; 178(1): 42 - 49. [Abstract] [Full Text] [PDF]

				P. Schelstraete, S. Van daele, K. De Boeck, M. Proesmans, P. Lebecque, J. Leclercq-Foucart, A. Malfroot, M. Vaneechoutte, and F. De Baets Pseudomonas aeruginosa in the home environment of newly infected cystic fibrosis patients Eur. Respir. J., April 1, 2008; 31(4): 822 - 829. [Abstract] [Full Text] [PDF]

				C. Etherington, M. Hall, S. Conway, D. Peckham, and M. Denton Clinical impact of reducing routine susceptibility testing in chronic Pseudomonas aeruginosa infections in cystic fibrosis J. Antimicrob. Chemother., February 1, 2008; 61(2): 425 - 427. [Abstract] [Full Text] [PDF]

				J. B. Bulitta, S. B. Duffull, M. Kinzig-Schippers, U. Holzgrabe, U. Stephan, G. L. Drusano, and F. Sorgel Systematic Comparison of the Population Pharmacokinetics and Pharmacodynamics of Piperacillin in Cystic Fibrosis Patients and Healthy Volunteers Antimicrob. Agents Chemother., July 1, 2007; 51(7): 2497 - 2507. [Abstract] [Full Text] [PDF]

				G. Doring, C. Meisner, M. Stern, and for the Flagella Vaccine Trial Study Group A double-blind randomized placebo-controlled phase III study of a Pseudomonas aeruginosa flagella vaccine in cystic fibrosis patients PNAS, June 26, 2007; 104(26): 11020 - 11025. [Abstract] [Full Text] [PDF]

				A. M. Weisner, H. Chart, A. Bush, J. C. Davies, and T. L. Pitt Detection of antibodies to Pseudomonas aeruginosa in serum and oral fluid from patients with cystic fibrosis J. Med. Microbiol., May 1, 2007; 56(5): 670 - 674. [Abstract] [Full Text] [PDF]

				A. K. Marr, J. Overhage, M. Bains, and R. E. W. Hancock The Lon protease of Pseudomonas aeruginosa is induced by aminoglycosides and is involved in biofilm formation and motility Microbiology, February 1, 2007; 153(2): 474 - 482. [Abstract] [Full Text] [PDF]

				S. Van daele, M. Vaneechoutte, K. De Boeck, C. Knoop, A. Malfroot, P. Lebecque, J. Leclercq-Foucart, L. Van Schil, K. Desager, and F. De Baets Survey of Pseudomonas aeruginosa genotypes in colonised cystic fibrosis patients Eur. Respir. J., October 1, 2006; 28(4): 740 - 747. [Abstract] [Full Text] [PDF]

				M Kappler, A Kraxner, D Reinhardt, B Ganster, M Griese, and T Lang Diagnostic and prognostic value of serum antibodies against Pseudomonas aeruginosa in cystic fibrosis Thorax, August 1, 2006; 61(8): 684 - 688. [Abstract] [Full Text] [PDF]

				M. Proesmans, W. Balinska-Miskiewicz, L. Dupont, X. Bossuyt, J. Verhaegen, N. Hoiby, and K. de Boeck Evaluating the "Leeds criteria" for Pseudomonas aeruginosa infection in a cystic fibrosis centre. Eur. Respir. J., May 1, 2006; 27(5): 937 - 943. [Abstract] [Full Text] [PDF]

				F. Ratjen, E. Rietschel, D. Kasel, R. Schwiertz, K. Starke, H. Beier, S. van Koningsbruggen, and H. Grasemann Pharmacokinetics of inhaled colistin in patients with cystic fibrosis J. Antimicrob. Chemother., February 1, 2006; 57(2): 306 - 311. [Abstract] [Full Text] [PDF]

				A. B. Chang and W. B. Glomb Guidelines for Evaluating Chronic Cough in Pediatrics: ACCP Evidence-Based Clinical Practice Guidelines Chest, January 1, 2006; 129(1_suppl): 260S - 283S. [Abstract] [Full Text] [PDF]

				S. M. Moskowitz, J. M. Foster, J. C. Emerson, R. L. Gibson, and J. L. Burns Use of Pseudomonas biofilm susceptibilities to assign simulated antibiotic regimens for cystic fibrosis airway infection J. Antimicrob. Chemother., November 1, 2005; 56(5): 879 - 886. [Abstract] [Full Text] [PDF]

				D. Hill, B. Rose, A. Pajkos, M. Robinson, P. Bye, S. Bell, M. Elkins, B. Thompson, C. MacLeod, S. D. Aaron, et al. Antibiotic Susceptibilities of Pseudomonas aeruginosa Isolates Derived from Patients with Cystic Fibrosis under Aerobic, Anaerobic, and Biofilm Conditions J. Clin. Microbiol., October 1, 2005; 43(10): 5085 - 5090. [Abstract] [Full Text] [PDF]

				J. L. Blumer, L. Saiman, M. W. Konstan, and D. Melnick The Efficacy and Safety of Meropenem and Tobramycin vs Ceftazidime and Tobramycin in the Treatment of Acute Pulmonary Exacerbations in Patients With Cystic Fibrosis Chest, October 1, 2005; 128(4): 2336 - 2346. [Abstract] [Full Text] [PDF]

				A. M. Jones Eradication therapy for early Pseudomonas aeruginosa infection in CF: many questions still unanswered Eur. Respir. J., September 1, 2005; 26(3): 373 - 375. [Full Text] [PDF]

				G. Taccetti, S. Campana, F. Festini, M. Mascherini, and G. Doring Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients Eur. Respir. J., September 1, 2005; 26(3): 458 - 461. [Abstract] [Full Text] [PDF]

				M. I. Morosini, M. Garcia-Castillo, E. Loza, M. Perez-Vazquez, F. Baquero, and R. Canton Breakpoints for Predicting Pseudomonas aeruginosa Susceptibility to Inhaled Tobramycin in Cystic Fibrosis Patients: Use of High-Range Etest Strips J. Clin. Microbiol., September 1, 2005; 43(9): 4480 - 4485. [Abstract] [Full Text] [PDF]

				R. Corech, A. Rao, A. Laxova, J. Moss, M. J. Rock, Z. Li, M. R. Kosorok, M. L. Splaingard, P. M. Farrell, and J. T. Barbieri Early Immune Response to the Components of the Type III System of Pseudomonas aeruginosa in Children with Cystic Fibrosis J. Clin. Microbiol., August 1, 2005; 43(8): 3956 - 3962. [Abstract] [Full Text] [PDF]

				S. G. Van daele, H. Franckx, R. Verhelst, P. Schelstraete, F. Haerynck, L. Van Simaey, G. Claeys, M. Vaneechoutte, and F. de Baets Epidemiology of Pseudomonas aeruginosa in a cystic fibrosis rehabilitation centre Eur. Respir. J., March 1, 2005; 25(3): 474 - 481. [Abstract] [Full Text] [PDF]

				R. Kraemer, A. Blum, A. Schibler, R. A. Ammann, and S. Gallati Ventilation Inhomogeneities in Relation to Standard Lung Function in Patients with Cystic Fibrosis Am. J. Respir. Crit. Care Med., February 15, 2005; 171(4): 371 - 378. [Abstract] [Full Text] [PDF]

				E. Kugelberg, S. Lofmark, B. Wretlind, and D. I. Andersson Reduction of the fitness burden of quinolone resistance in Pseudomonas aeruginosa J. Antimicrob. Chemother., January 1, 2005; 55(1): 22 - 30. [Abstract] [Full Text] [PDF]

				B. Curran, D. Jonas, H. Grundmann, T. Pitt, and C. G. Dowson Development of a Multilocus Sequence Typing Scheme for the Opportunistic Pathogen Pseudomonas aeruginosa J. Clin. Microbiol., December 1, 2004; 42(12): 5644 - 5649. [Abstract] [Full Text] [PDF]

				F. W. Scott and T. L. Pitt Identification and characterization of transmissible Pseudomonas aeruginosa strains in cystic fibrosis patients in England and Wales J. Med. Microbiol., July 1, 2004; 53(7): 609 - 615. [Abstract] [Full Text] [PDF]

				K. De Boeck, A. Malfroot, L. Van Schil, P. Lebecque, C. Knoop, J.R.W. Govan, C. Doherty, S. Laevens, and P. Vandamme Epidemiology of Burkholderia cepacia complex colonisation in cystic fibrosis patients Eur. Respir. J., June 1, 2004; 23(6): 851 - 856. [Abstract] [Full Text] [PDF]

				K. Decaestecker, E. Decaestecker, C. Castellani, M. Jaspers, H. Cuppens, and K. De Boeck Genotype/phenotype correlation of the G85E mutation in a large cohort of cystic fibrosis patients Eur. Respir. J., May 1, 2004; 23(5): 679 - 684. [Abstract] [Full Text] [PDF]

				A. Dubouix, C. Campanac, J. Fauvel, M.-F. Simon, J.-P. Salles, C. Roques, H. Chap, and N. Marty Bactericidal properties of group IIa secreted phospholipase A2 against Pseudomonas aeruginosa clinical isolates J. Med. Microbiol., December 1, 2003; 52(12): 1039 - 1045. [Abstract] [Full Text] [PDF]

				R. L. Gibson, J. L. Burns, and B. W. Ramsey Pathophysiology and Management of Pulmonary Infections in Cystic Fibrosis Am. J. Respir. Crit. Care Med., October 15, 2003; 168(8): 918 - 951. [Abstract] [Full Text] [PDF]

				T L Pitt, M Sparrow, M Warner, and M Stefanidou Survey of resistance of Pseudomonas aeruginosa from UK patients with cystic fibrosis to six commonly prescribed antimicrobial agents Thorax, September 1, 2003; 58(9): 794 - 796. [Abstract] [Full Text] [PDF]

				K. H.-V. Tan, M. Mulheran, A. J. Knox, and A. R. Smyth Aminoglycoside Prescribing and Surveillance in Cystic Fibrosis Am. J. Respir. Crit. Care Med., March 15, 2003; 167(6): 819 - 823. [Full Text] [PDF]

				J. B. Lyczak, C. L. Cannon, and G. B. Pier Lung Infections Associated with Cystic Fibrosis Clin. Microbiol. Rev., April 1, 2002; 15(2): 194 - 222. [Abstract] [Full Text] [PDF]

				N. Hoiby New antimicrobials in the management of cystic fibrosis J. Antimicrob. Chemother., February 1, 2002; 49(2): 235 - 238. [Full Text] [PDF]

				T. Schulin In vitro activity of the aerosolized agents colistin and tobramycin and five intravenous agents against Pseudomonas aeruginosa isolated from cystic fibrosis patients in southwestern Germany J. Antimicrob. Chemother., February 1, 2002; 49(2): 403 - 406. [Abstract] [Full Text] [PDF]

				N HOIBY Antibodies against Pseudomonas aeruginosa in patients with bronchiectasis: helpful or harmful? Thorax, September 1, 2001; 56(9): 667 - 668. [Full Text] [PDF]